BERKELEY HEIGHTS, N.J., Jan. 25, 2016 /PRNewswire/ -- Vertice Pharma today announced that it has appointed Dr. Indranil Nandi as Vice President, Research & Development effective today.
"We are delighted to welcome Dr. Nandi to the Vertice Pharma leadership team. Dr. Nandi brings over 15 years of extensive multi-disciplinary expertise in drug development and portfolio management across a broad range of therapeutic areas and dosage forms. Dr. Nandi has a proven track record in drug development and I have every confidence in his ability to lead Vertice's Research & Development efforts. His extensive network and his experience in progressing collaborative projects will be key to building an even more robust product pipeline and driving our growth strategy," said Don DeGolyer, President & Chief Executive Officer of Vertice Pharma.
"I am thrilled to be joining Vertice Pharma at such an exciting time and I look forward to growing our product pipeline with Don and the entire Vertice Pharma leadership team." Most recently, Dr. Nandi has served as Vice President, Generic Research & Development for Impax Laboratories. Prior to joining Impax, Dr. Nandi held positions of increasing responsibilities at Sandoz, including his last position as Executive Director, Portfolio, Project Management and Scientific Affairs. He also worked in various positions in R&D at Par Pharmaceuticals and Geneva Pharmaceuticals.
Dr. Nandi earned a Master of Business Administration from Rutgers, State University of NJ; a Ph.D. in Pharmaceutical Sciences from St. John's University, NY and a Master's degree in Pharmacy from Birla Institute of Technology and Sciences in India, and has co-authored various scientific publications and patents and patent applications.
About Vertice Pharma
Vertice Pharma is a specialty pharmaceuticals company focused on improving patients' health. Vertice Pharma develops, manufactures, markets, and distributes high-quality and affordable pharmaceutical products through its operating companies. Vertice Pharma has global headquarters in the United Kingdom and United States headquarters in New Jersey.
For more information visit www.verticepharma.com
Kellen Johnson - Kellen.Johnson@verticepharma.com
SOURCE Vertice Pharma